<DOC>
	<DOCNO>NCT00003451</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine interleukin-12 interferon alfa treat patient residual , recurrent , metastatic malignant melanoma advance cancer respond standard therapy . Interleukin-12 may stimulate person 's white blood cell kill cancer cell . Interferon alfa may interfere growth cancer cell . Combining interleukin-12 interferon alfa may kill cancer cell .</brief_summary>
	<brief_title>Interleukin-12 Followed Interferon Alfa Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose interferon alfa precede single dose interleukin-12 patient recurrent metastatic melanoma advance malignancy . OUTLINE : This dose-escalation study . Cohorts 3 patient receive interleukin-12 IV push day 1 , follow escalate dos interferon alfa subcutaneous injection 24 , 48 , 72 , 96 120 hour . Courses repeat every 2 week 6 month ( 12 course total ) absence unacceptable toxicity disease progression . Patients achieve partial response stable disease completion 6 month therapy may receive additional course therapy 24 month . Dose escalation interferon alfa continue subsequent cohort absence dose limit toxicity ( DLT ) . If 1 3 patient experience DLT dose level , 3 additional patient enter dose level . If 2 6 patient experience DLT , dose escalation stop . The maximum tolerate dose define 1 level dose 2 6 patient experience DLT . Patients follow every 3 month 1 year every 6 month thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm residual , recurrent , metastatic malignant melanoma advanced malignancy Must fail standard curative and/or palliative therapy No brain central nervous system metastases PATIENT CHARACTERISTICS : Age : 13 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL ( may posttransfusion may receive erythropoietin ) Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Creatinine great 1.5 time ULN Creatinine clearance least 60 mL/min Calcium great 11 mg/dL ( may receive agent decrease calcium ) No significant cardiovascular disease No cardiac arrhythmia require drug device intervention No history significant peripheral neuropathy No significant central nervous system disease HIV negative Hepatitis B surface antigen negative No concurrent serious infection require intravenous antibiotic therapy No clinically significant autoimmune disease ( i.e. , rheumatoid arthritis ) No clinically significant gastrointestinal bleeding uncontrolled peptic ulcer disease No history inflammatory bowel disease No major illness substantially increase risk associate participation study Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : At least 4 week since prior biologic therapy At least 4 week since prior chemotherapy No concurrent systemic corticosteroid At least 2 week since prior local radiotherapy At least 2 week since surgery Other : At least 4 week since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>